The Global Platform for the Prevention of Autoimmune Diabetes is a multicenter European initiative to provide a framework for T1D primary prevention trials such as POInT (Primary Oral Insulin Trial)22,36. This evidence concerns the gene INS and type 1 diabetes mellitus.